ALS drug trial halted early: what happened?
NCT ID NCT03757351
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental drug called DNL747 in 15 people with ALS to see if it was safe and how the body processed it. The study was terminated before completion, so we don't have full results. It was a small, short-term safety study, not a test of whether the drug can treat ALS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNL747
What this could lead to
If successful, this could point toward a treatment to slow ALS progression, but the trial was terminated early, so no conclusions can be drawn.
What could go wrong
This was a very early (Phase 1) safety study with only 15 participants, and it was terminated before completion. There is no evidence yet that DNL747 works for ALS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bioclinica
Orlando, Florida, 32806, United States
-
CHDR
Leiden, South Holland, 2333, Netherlands
-
PRA Health Sciences
Salt Lake City, Utah, 84124, United States